Literature DB >> 21076615

Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden.

Peter J Klover1, William J Muller, Gertraud W Robinson, Ruth M Pfeiffer, Daisuke Yamaji, Lothar Hennighausen.   

Abstract

Type I and type II classes of interferons (IFNs) signal through the JAK/STAT1 pathway and are known to be important in adaptive and innate immune responses and in protection against tumors. Although STAT1 is widely considered a tumor suppressor, it remains unclear, however, if this function occurs in tumor cells (cell autonomous) or if STAT1 acts primarily through immune cells. Here, the question of whether STAT1 has a cell autonomous role in mammary tumor formation was addressed in a mouse model of ERBB2/neu-induced breast cancer in the absence and presence of STAT1. For this purpose, mice that carry floxed Stat1 alleles, which permit cell-specific removal of STAT1, were generated. To induce tumors only in mammary cells lacking STAT1, Stat1 floxed mice were crossed with transgenic mice that express cre recombinase and the neu oncogene under the mouse mammary tumor virus LTR (Stat1fl/fl NIC). Stat1 was effectively deleted in mammary epithelium of virgin Stat1fl/fl NIC females. Time-to-tumor onset was significantly shorter in Stat1fl/fl NIC females than in WT NIC (Wilcoxon rank sum test, P = .02). The median time-to-tumor onset in the Stat1fl/fl NIC mice was 49.4 weeks, whereas it was 62.4 weeks in the WT NIC mice. These results suggest that STAT1 in mammary epithelial cells may play a role in suppressing tumorigenesis. The Stat1 floxed allele described in this study is also a unique resource to determine the cellular targets of IFNs and STAT1 action, which should aid our understanding and appreciation of these pathways.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21076615      PMCID: PMC2978912          DOI: 10.1593/neo.10716

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  20 in total

Review 1.  Type I interferon receptors: biochemistry and biological functions.

Authors:  Nicole A de Weerd; Shamith A Samarajiwa; Paul J Hertzog
Journal:  J Biol Chem       Date:  2007-05-14       Impact factor: 5.157

2.  Cre-mediated gene deletion in the mammary gland.

Authors:  K U Wagner; R J Wall; L St-Onge; P Gruss; A Wynshaw-Boris; L Garrett; M Li; P A Furth; L Hennighausen
Journal:  Nucleic Acids Res       Date:  1997-11-01       Impact factor: 16.971

3.  STAT1 acts as a tumor promoter for leukemia development.

Authors:  Boris Kovacic; Dagmar Stoiber; Richard Moriggl; Eva Weisz; René G Ott; Rita Kreibich; David E Levy; Hartmut Beug; Michael Freissmuth; Veronika Sexl
Journal:  Cancer Cell       Date:  2006-07       Impact factor: 31.743

4.  ShcA signalling is essential for tumour progression in mouse models of human breast cancer.

Authors:  Josie Ursini-Siegel; W Rod Hardy; Dongmei Zuo; Sonya H L Lam; Virginie Sanguin-Gendreau; Robert D Cardiff; Tony Pawson; William J Muller
Journal:  EMBO J       Date:  2008-02-14       Impact factor: 11.598

5.  Osteopontin regulates ubiquitin-dependent degradation of Stat1 in murine mammary epithelial tumor cells.

Authors:  Chengjiang Gao; Zhiyong Mi; Hongtao Guo; Paul C Kuo
Journal:  Neoplasia       Date:  2007-09       Impact factor: 5.715

Review 6.  Next generation of immunotherapy for melanoma.

Authors:  John M Kirkwood; Ahmad A Tarhini; Monica C Panelli; Stergios J Moschos; Hassane M Zarour; Lisa H Butterfield; Helen J Gogas
Journal:  J Clin Oncol       Date:  2008-07-10       Impact factor: 44.544

7.  Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease.

Authors:  J E Durbin; R Hackenmiller; M C Simon; D E Levy
Journal:  Cell       Date:  1996-02-09       Impact factor: 41.582

Review 8.  Insights from transgenic mouse models of ERBB2-induced breast cancer.

Authors:  Josie Ursini-Siegel; Babette Schade; Robert D Cardiff; William J Muller
Journal:  Nat Rev Cancer       Date:  2007-04-19       Impact factor: 60.716

9.  An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer.

Authors:  Ralph R Weichselbaum; Hemant Ishwaran; Taewon Yoon; Dimitry S A Nuyten; Samuel W Baker; Nikolai Khodarev; Andy W Su; Arif Y Shaikh; Paul Roach; Bas Kreike; Bernard Roizman; Jonas Bergh; Yudi Pawitan; Marc J van de Vijver; Andy J Minn
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-10       Impact factor: 11.205

10.  Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease.

Authors:  Ariane Chapgier; Stéphanie Boisson-Dupuis; Emmanuelle Jouanguy; Guillaume Vogt; Jacqueline Feinberg; Ada Prochnicka-Chalufour; Armanda Casrouge; Kun Yang; Claire Soudais; Claire Fieschi; Orchidée Filipe Santos; Jacinta Bustamante; Capucine Picard; Ludovic de Beaucoudrey; Jean-François Emile; Peter D Arkwright; Robert D Schreiber; Claudia Rolinck-Werninghaus; Angela Rösen-Wolff; Klaus Magdorf; Joachim Roesler; Jean-Laurent Casanova
Journal:  PLoS Genet       Date:  2006-08-18       Impact factor: 5.917

View more
  63 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Stat1 stimulates cap-independent mRNA translation to inhibit cell proliferation and promote survival in response to antitumor drugs.

Authors:  Shuo Wang; Christos Patsis; Antonis E Koromilas
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

3.  Tumor-induced Stromal STAT1 Accelerates Breast Cancer via Deregulating Tissue Homeostasis.

Authors:  Victoria R Zellmer; Patricia M Schnepp; Sarah L Fracci; Xuejuan Tan; Erin N Howe; Siyuan Zhang
Journal:  Mol Cancer Res       Date:  2017-01-20       Impact factor: 5.852

4.  The differential interferon responses of two strains of Stat1-deficient mice do not alter susceptibility to HSV-1 and VSV in vivo.

Authors:  Sarah Katzenell; Yufei Chen; Zachary M Parker; David A Leib
Journal:  Virology       Date:  2014-01-14       Impact factor: 3.616

Review 5.  Genetically engineered ERα-positive breast cancer mouse models.

Authors:  Sarah A Dabydeen; Priscilla A Furth
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

6.  IL-27 is required for shaping the magnitude, affinity distribution, and memory of T cells responding to subunit immunization.

Authors:  Nathan D Pennock; Laurent Gapin; Ross M Kedl
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

7.  Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Authors:  Edit Porpaczy; Sabrina Tripolt; Andrea Hoelbl-Kovacic; Bettina Gisslinger; Zsuzsanna Bago-Horvath; Emilio Casanova-Hevia; Emmanuelle Clappier; Thomas Decker; Sabine Fajmann; Daniela A Fux; Georg Greiner; Sinan Gueltekin; Gerwin Heller; Harald Herkner; Gregor Hoermann; Jean-Jacques Kiladjian; Thomas Kolbe; Christoph Kornauth; Maria-Theresa Krauth; Robert Kralovics; Leonhard Muellauer; Mathias Mueller; Michaela Prchal-Murphy; Eva Maria Putz; Emmanuel Raffoux; Ana-Iris Schiefer; Klaus Schmetterer; Christine Schneckenleithner; Ingrid Simonitsch-Klupp; Cathrin Skrabs; Wolfgang R Sperr; Philipp Bernhard Staber; Birgit Strobl; Peter Valent; Ulrich Jaeger; Heinz Gisslinger; Veronika Sexl
Journal:  Blood       Date:  2018-06-14       Impact factor: 22.113

8.  Adaptive Immune Regulation of Mammary Postnatal Organogenesis.

Authors:  Vicki Plaks; Bijan Boldajipour; Jelena R Linnemann; Nguyen H Nguyen; Kelly Kersten; Yochai Wolf; Amy-Jo Casbon; Niwen Kong; Renske J E van den Bijgaart; Dean Sheppard; Andrew C Melton; Matthew F Krummel; Zena Werb
Journal:  Dev Cell       Date:  2015-08-27       Impact factor: 12.270

9.  The milk protein α-casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis.

Authors:  Gloria Bonuccelli; Remedios Castello-Cros; Franco Capozza; Ubaldo E Martinez-Outschoorn; Zhao Lin; Aristotelis Tsirigos; Jiao Xuanmao; Diana Whitaker-Menezes; Anthony Howell; Michael P Lisanti; Federica Sotgia
Journal:  Cell Cycle       Date:  2012-10-09       Impact factor: 4.534

10.  Programmable nanoparticle functionalization for in vivo targeting.

Authors:  Hua Pan; Jacob W Myerson; Lingzhi Hu; Jon N Marsh; Kirk Hou; Michael J Scott; John S Allen; Grace Hu; Susana San Roman; Gregory M Lanza; Robert D Schreiber; Paul H Schlesinger; Samuel A Wickline
Journal:  FASEB J       Date:  2012-10-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.